BEHOLD-Endometrial01
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
- NCT07286331 ↗
- Recruiting
- GlaxoSmithKline
- Focused
We haven't built an HCP commentary report on BEHOLD-Endometrial01 (mocertatug rezetecan in endometrial cancer after platinum-based chemotherapy and immunotherapy) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BEHOLD-Endometrial01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Neoplasms, Endometrial
- Interventions
- Mocertatug rezetecan; Paclitaxel; Doxorubicin
- Arms
- Mocertatug rezetecan · Experimental
- Standard of Care · Active comparator
- Enrollment
- 600 (estimated)
- Primary outcomes
- Objective response rate (ORR) by BICR
- Progression Free Survival (PFS) by BICR
- Sponsor
- GlaxoSmithKline with ENGOT, GOG, APGOT
- Start
- Jun 4, 2026
- Primary completion
- Feb 29, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT07286331 · updated Oct 2, 2026